Equities research analysts at Benchmark initiated coverage on shares of Milestone Scientific (NYSE:MLSS – Get Free Report) in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage set a “speculative buy” rating and a $1.25 price target on the stock. Benchmark’s target price would suggest a potential upside of 43.68% from the stock’s current price.
Separately, StockNews.com started coverage on shares of Milestone Scientific in a research report on Wednesday. They set a “hold” rating for the company.
Get Our Latest Stock Report on MLSS
Milestone Scientific Price Performance
Milestone Scientific (NYSE:MLSS – Get Free Report) last posted its quarterly earnings results on Thursday, August 15th. The company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). Milestone Scientific had a negative return on equity of 60.78% and a negative net margin of 54.87%. The business had revenue of $1.85 million during the quarter.
Insider Buying and Selling
In other news, Director Leonard Osser sold 141,913 shares of the company’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $0.95, for a total transaction of $134,817.35. Following the sale, the director now directly owns 4,602,506 shares in the company, valued at approximately $4,372,380.70. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders have sold 143,122 shares of company stock worth $136,026. Corporate insiders own 24.75% of the company’s stock.
About Milestone Scientific
Milestone Scientific Inc, a biomedical technology research and development company, patents, designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates through Dental and Medical segments.
Further Reading
- Five stocks we like better than Milestone Scientific
- Energy and Oil Stocks Explained
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- Are Penny Stocks a Good Fit for Your Portfolio?
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- How to Calculate Inflation Rate
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for Milestone Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Scientific and related companies with MarketBeat.com's FREE daily email newsletter.